Rocket
Premium
Excel Add-In
International
Tools
Dashboard
Screener
Spinoffs
IPOs
Register
Alerts
Sign In
Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Inv. presentation
Appointed director
Quarterly results
CC transcript
HUMAN GENOME SCIENCES INC (HGSI)
Create:
Alert
All
|
News
|
Filings
Date Filed
Type
Description
07/21/2011
BW
Human Genome Sciences Announces Second Quarter 2011 Financial Results and Key Developments
07/14/2011
BW
Human Genome Sciences to Sponsor Conference Call to Discuss Second Quarter 2011 Financial Results
06/06/2011
BW
Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Goldman Sachs Conference
05/20/2011
BW
Human Genome Sciences to Host May 20 Conference Call to Discuss the Positive Opinion Received in Europe from the CHMP for BENLYSTA® (Belimumab)
05/20/2011
BW
GlaxoSmithKline and Human Genome Sciences Receive Positive Opinion in Europe from the CHMP for BENLYSTA® (Belimumab)
05/02/2011
BW
Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Deutsche Bank Conference
04/28/2011
BW
Human Genome Sciences Announces First Quarter 2011 Financial Results and Key Developments
04/14/2011
BW
Human Genome Sciences Updates Investors on Progress of BENLYSTA® Launch and Future Priorities
04/12/2011
MW
Rich Pipelines Send Biotech Stocks Soaring
04/07/2011
BW
Human Genome Sciences Invites Investors to Listen to Webcast of Presentations at Analyst & Investor Meeting
03/16/2011
BW
Human Genome Sciences and FivePrime Therapeutics Announce Development and Commercialization Agreement for Novel Anti-Cancer Drug
03/14/2011
BW
Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Barclays Capital Conference
03/14/2011
BW
Human Genome Sciences Appoints George Morrow to its Board of Directors
03/09/2011
BW
Human Genome Sciences and GlaxoSmithKline Announce FDA Approval of BENLYSTA® (Belimumab) for Treatment of Systemic Lupus Erythematosus
03/03/2011
BW
Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Cowen and Company Conference
02/25/2011
BW
Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at RBC Capital Conference
02/24/2011
BW
Human Genome Sciences Announces Fourth-Quarter and Full-Year Financial Results and Key Developments
02/15/2011
BW
Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Leerink Swann Conference
02/11/2011
BW
Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BIO CEO and Investor Conference
02/10/2011
BW
Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at ISI Annual Conference
01/14/2011
MW
Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Human Genome Sciences, Inc. to Inquire About the Lead Plaintiff Position in Securities Fraud Class Action Lawsuit
12/14/2010
BW
Human Genome Sciences Appoints Colin Goddard, Ph.D., to Its Board of Directors
12/03/2010
BW
Human Genome Sciences and GlaxoSmithKline Announce FDA Extension of BENLYSTA® PDUFA Target Date to March 10, 2011
11/16/2010
BW
Human Genome Sciences and GlaxoSmithKline Announce Vote of FDA Advisory Committee to Recommend Approval of BENLYSTA® for Systemic Lupus Erythematosus
10/27/2010
BW
Human Genome Sciences Announces Third Quarter 2010 Financial Results and Key Developments
09/23/2010
BW
Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at JMP Securities Healthcare Conference
09/16/2010
BW
Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at UBS Healthcare Conference
09/14/2010
BW
Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Stifel Nicolaus Healthcare Conference
09/09/2010
BW
Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Morgan Stanley Healthcare Conference
08/19/2010
BW
Human Genome Sciences and GlaxoSmithKline Announce FDA Priority Review Designation for BENLYSTA® (belimumab) as a Potential Treatment for Systemic Lupus Erythematosus
08/13/2010
BW
Human Genome Sciences Names Tuomo Pätsi Vice President, HGS Europe
07/28/2010
MW
Analytical Reports on Human Genome Science and Genzyme -- Biotech Stocks Under Stress
07/22/2010
BW
Human Genome Sciences Announces Second Quarter 2010 Financial Results and Key Developments
07/13/2010
BW
Human Genome Sciences and Lonza Enter Commercial Manufacturing Agreement for BENLYSTA®, a Potential New Treatment for Systemic Lupus Erythematosus
Next >>
Rocket Data Systems, Inc. © 2019 |
Contact Us
|
Data Disclaimer
|
Terms of Use
|
Privacy